The structure-activity correlation on the inhibitory effects of flavonoids on cytochrome P450 3A activity

Biological and Pharmaceutical Bulletin

Volumn 32, Issue 4, 2009, Pages 671-676

  Tsujimoto, Masayuki ^a   Horie, Maya ^a   Honda, Hiroko ^a   Takara, Kohji ^a   Nishiguchi, Kohshi ^a  

^a KYOTO PHARMACEUTICAL UNIVERSITY   (Japan)

Author keywords

Basal structure; Cytochrome p450 3a; Flavonoid; Structure activity correlation

Indexed keywords

3 HYDROXYFLAVONE; 7 HYDROXYFLAVANONE; 7 HYDROXYFLAVONE; ACACETIN; BAICALEIN; CHRYSIN; CYTOCHROME P450 3A; CYTOCHROME P450 3A4; DAIDZEIN; DIOSMETIN; ERIODICTYOL; FLAVANONE; FLAVANONE DERIVATIVE; FLAVONE; FLAVONOID; GENISTEIN; HESPERETIN; ISOFLAVONE; KAEMPFEROL; LUTEOLIN; MORIN; MYRICETIN; NARINGENIN; PINOCEMBRINE; PRIMULETIN; QUERCETIN; TAXIFOLIN; UNCLASSIFIED DRUG;

ARTICLE; CONCENTRATION RESPONSE; DRUG ACTIVITY; DRUG EFFECT; DRUG STRUCTURE; HUMAN; HUMAN CELL; HYDROXYLATION; IC 50; INHIBITION KINETICS; LIVER MICROSOME; MAXIMUM ALLOWABLE CONCENTRATION; STRUCTURE ACTIVITY RELATION;

CYTOCHROME P-450 CYP3A; ENZYME INHIBITORS; FLAVONOIDS; HUMANS; HYDROXYLATION; MICROSOMES, LIVER; MULTIVARIATE ANALYSIS; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 65249093693     PISSN: 09186158     EISSN: 13475215     Source Type: Journal    
DOI: 10.1248/bpb.32.671     Document Type: Article

References (16)

1. Havsteen B., Biochem. Pharmacol, 32, 1141-1148 (1983).
2. Middleton E. Jr., Kandaswami C., Theoharides T. C., Pharmacol. Rev., 52, 673-751 (2000).
3. Mojzisova G., Kuchta M., Physiol. Res., 50, 529-535 (2001).
4. Havsteen B. H., Pharmacol. Ther., 96, 67-202 (2002).
5. Nelson D. R., Kamataki T., Waxman D. J., guengerich F. P., Estabrook R. W., Feyereisen R., Gonzalez F. J., Coon M. J., Gunsalus I. C., Gotoh O., Okuda K., Nebert W., DNA Cell Biol., 12, 1-51 (1993).
6. von Moltke L. L., Weemhoff J. L., Bedir E., Khan I. A., Harmatz J. S., Goldman P., Greenblatt D. J., J. Pharm. Pharmacol., 56, 1039-1044 (2004).
7. Ho P. C., Saville D. J., J. Pharm. Pharm. Sci., 4, 217-227 (2001).
8. Quintieri L., Palatini P., Nassi A., Ruzza P., Floreani M., Biochem. Pharmacol., 75, 1426-1437 (2008).
9. Nishikawa M., Ariyoshi N., Kotani A., Ishii I., Nakamura H., Nakasa H., Ida M., Nakamura H., Kimura N., Kimura M., Hasegawa A., Kusu F., Ohmori S., Nakazawa K., Kitada M., Drug Metab. Pharmacokinet., 19, 280-289 (2004).
10. Yamaoka K., Tanigawara Y., Nakagawa T., Uno T., J. Pharmacobio - dyn., 4, 879-885 (1981).
11. Lewis D. F., Lake B. G., Dickins M., J. EnzymeInhib. Med. Chem., 21, 127-132 (2006).
12. Kitagawa S., Nabekura T., Takahashi T., Nakamura Y., Sakamoto H., Tano H., Hirai M., Tsukahara G., Biol. Pharm. Bull., 28, 2274-2278 (2005).
13. Kim H. J., Lee S. B., Park S. K., Kim H. M. Park Y. I., Dong M. S., Arch. Pharm. Res., 28, 1114-1121 (2005).
14. Breinholt V. M., Offord E. A., Brouwer C., Nielsen S. E., Brosen K., Friedberg T., Food Chem. Toxicol., 40, 609-616 (2002).
15. Zhang S., Yang X., Coburn R. A., Morris M. E., Biochem. Pharmacol., 70, 627-639 (2005).
16. Beyeler S., Testa B., Perrissoud D., Biochem. Pharmacol., 37, 1971-1979 (1988).